Strand Therapeutics vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $153M Series B (Aug 2025). $256M total. Programmable mRNA with SignalLock tumor-sensing logic gates. STX-003 IV delivery entering clinic 2026. Phase 1 confirmed CR at ASCO 2025.
About
Strand Therapeutics is developing programmable mRNA — modified messenger RNA that incorporates synthetic gene circuits (logic gates) that restrict therapeutic protein expression to the tumor microenvironment. The company raised $153 million in Series B financing in August 2025, bringing total funding to $256 million at a ~$571 million valuation. Strand presented Phase 1 data at ASCO 2025 showing a confirmed complete response for STX-001, and its STX-003 program — which uses intravenous delivery rather than intratumoral injection — is entering clinical testing in 2026.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Strand Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.